12 recruiting, 9 active not recruiting, 7 terminated, 3 withdrawn. 20 Phase 2, 16 Phase 1, 2 Phase 3.
Follow loncastuximab tesirine: new trials by email Literature Review of loncastuximab tesirine trials Research Report on loncastuximab tesirine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Loncastuximab Tesirine and Rituximab as First-line Therapy in Patients With Post-transplant Lymphoproliferative Disorder (PLUTO) Loncastuximab tesirine, Rituximab or rituximab biosimilar - Post-transplant Lymphoproliferative Disorder | Phase 1 / Phase 2 | Not yet recruiting | University of Utah | 23 | 2026-11-01 | 2026-10-09 |
| A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies JNJ-95566692, JNJ-87801493, loncastuximab tesirine - Lymphoma, Non-Hodgkin | Phase 1 | Recruiting | Janssen Research & Development, LLC | 340 | 2026-01-20 | 2026-09-10 |
| Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma Epcoritamab, Loncastuximab Tesirine - Large B-cell Lymphoma, Relapse | Phase 2 | Recruiting | University of Miami | 26 | 2026-01-07 | 2026-10-15 |
| Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab Tesirine and Epcoritamab - Aggressive Diffuse Large B-cell Lymphoma, High-grade B-cell Lymphoma (HGBL) | Phase 2 | Recruiting | Universität Münster | 120 | 2025-10-31 | 2026-07-30 |
| Loncastuximab Tesirine and Rituximab as Bridging Therapy Before Standard-of-care CAR-T Therapy in Patients With Large B-cell Lymphoma (CORAL) Loncastuximab Tesirine, Rituximab - Relapsed or Refractory Large B-cell Lymphoma | Phase 2 | Recruiting | University of Utah | 29 | 2025-08-25 | 2026-10-16 |
| Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab, Roflumilast, Rituximab - Diffuse Large B-cell Lymphoma | Phase 1 | Recruiting | The University of Texas Health Science Center at San Antonio | 10 | 2025-06-20 | 2026-09-29 |
| Loncastuximab Tesirine and Rituximab Following Stereotactic Radiosurgery in Patients With Central Nervous System Lymphomas (SOLAR) Loncastuximab tesirine and rituximab (Lonca-R) - Central Nervous System Lymphoma | Phase 1 | Recruiting | University of Utah | 12 | 2025-03-18 | 2026-08-10 |
| A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma Odronextamab, Loncastuximab tesirine, Rituximab - B-cell Non Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | University of Birmingham | 210 | 2024-05-02 | 2026-02-20 |
| Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma Biopsy, Biospecimen Collection, Computed Tomography - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 36 | 2024-01-02 | 2026-10-08 |
| Addition of Loncastuximab Tesirine to Acalbrutinib , Chronic Lymphocytic Leukemia Loncastuximab Tesirine and Acalabrutinib - Chronic Lymphocytic Leukemia | Phase 1 | Active not recruiting | University of Alabama at Birmingham | 24 | 2023-12-18 | 2026-10-20 |
| Loncastuximab Tesirine for the Treatment of Relapsed or Refractory B-Cell Malignancies Loncastuximab Tesirine, Bone Marrow Biopsy, Bone Marrow Aspiration - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma | Phase 2 | Terminated | University of Washington | 11 | 2023-08-07 | 2026-06-15 |
| A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10) Loncastuximab Tesirine - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma | Phase 1 | Terminated | ADC Therapeutics S.A. | 5 | 2023-07-28 | 2026-07-20 |
| Study of Loncastuximab Tesirine in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or High-Grade B-Cell Lymphoma (HGBCL) Following CAR-T Therapy Failure Loncastuximab Tesirine (Anti-CD19 Antibody-Drug Conjugate) - Diffuse Large B-Cell Lymphoma, High-grade B-cell Lymphoma (HGBCL) | Phase 2 | Recruiting | Istituto Clinico Humanitas | 50 | 2023-06-16 | 2025-04-09 |
| Loncastuximab Tesirine and Rituximab Followed by DA-EPOCH-R for Treating Patients With High-Risk Diffuse Large B-cell Lymphoma Cyclophosphamide, Doxorubicin, Etoposide - Double-Expressor Lymphoma, High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Phase 2 | Active not recruiting | University of California, Davis | 24 | 2023-05-24 | 2026-09-28 |
| Loncastuximab Tesirine in Combination With Chemotherapy Prior to Stem Cell Transplant for the Treatment of Recurrent or Refractory Diffuse Large B-Cell Lymphoma Autologous Hematopoietic Stem Cell Transplantation, Carmustine, Cytarabine - Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Phase 1 | Withdrawn | Fred Hutchinson Cancer Center | 2023-04-01 | 2023-01-13 | |
| A Study of MT-2111 in Patients With Relapsed/Refractory DLBCL MT-2111 - Diffuse Large B-Cell Lymphoma | Phase 1 / Phase 2 | Active not recruiting | Tanabe Pharma Corporation | 46 | 2023-01-30 | 2026-06-09 |
| Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies Etoposide, Doxorubicin, Cyclophosphamide - B-cell Lymphoma, Burkitt Lymphoma | Phase 1 | Active not recruiting | Medical College of Wisconsin | 11 | 2023-01-26 | 2026-10-14 |
| A Phase II Study of Loncastuximab Tesirine as Consolidation Strategy in Patients With LBCL in PR After CAR T-cell Therapy Loncastuximab Tesirine - Large B-cell Lymphoma, Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 30 | 2022-09-23 | 2026-07-15 |
| A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) Loncastuximab Tesirine, Rituximab - Diffuse Large B-cell Lymphoma | Phase 2 | Terminated | ADC Therapeutics S.A. | 41 | 2022-06-21 | 2025-01-30 |
| Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma Loncastuximab tesirine 150 µg/Kg, Loncastuximab tesirine 75µg/Kg - Marginal Zone Lymphoma | Phase 2 | Recruiting | University of Miami | 50 | 2022-06-21 | 2026-09-21 |
Showing 20 of 35. Sign in to see all of them.
Lymphoma, Large B-Cell, Diffuse (17) · Lymphoma (8) · Lymphoma, Follicular (6) · Lymphoma, Mantle-Cell (5) · Lymphoma, B-Cell (4) · Lymphoma, Non-Hodgkin (4) · Recurrence (4) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Waldenstrom Macroglobulinemia (2) · Dendritic Cell Sarcoma, Interdigitating (1) · Lymphoma, B-Cell, Marginal Zone (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)
ADC Therapeutics S.A. (12) · University of Utah (3) · University of Miami (2) · Barbara Ann Karmanos Cancer Institute (1) · City of Hope Medical Center (1) · Fondazione Italiana Linfomi - ETS (1) · Fred Hutchinson Cancer Center (1) · Istituto Clinico Humanitas (1) · Janssen Research & Development, LLC (1) · Juan P. Alderuccio, MD (1) · M.D. Anderson Cancer Center (1) · Medical College of Wisconsin (1) · Paolo Caimi, MD (1) · Shayna Sarosiek, MD (1) · Tanabe Pharma Corporation (1)
United States (28) · Italy (9) · Spain (7) · United Kingdom (7) · Belgium (6) · France (4) · Switzerland (3) · Australia (2) · Brazil (2) · Czechia (2) · Hungary (2) · Israel (2) · Japan (2) · Netherlands (2) · Poland (2)
Aditi Saha, M.D. (1) · Adolfo E Diaz Duque, MD (1) · Amos Burke (1) · Dipenkumar Modi, M.D. (1) · Izidore Lossos, MD (1) · Joseph M Tuscano (1) · Juan Alderuccio, MD (1) · Juan P Alderuccio, MD (1) · Marco Ladetto (1) · Mehdi Hamadani, MD (1) · Narendranath Epperla, MD (1) · Narendranath Epperla, MD, MS (1) · Narendranath Epperla, MD, MS, FACP (1)
PMID 34893942, PMID 31685491, PMID 32012214, PMID 33211842, PMID 33989558, PMID 34690090, PMID 35513980, PMID 37646659, PMID 37855688, PMID 39662486, PMID 40669032, PMID 41894687
2018 (2), 2016 (1), 2017 (1), 2023 (1), 2025 (1), P30CA033572 (1), P30CA093373 (1)